Increased incidence of venous thrombosis at uncommon sites is associated with JAK2V617F mutation in MPDs and thrombotic complications are more common in essential thrombocythemia (ET). Here, we describe 6-year-old girl with clonal myelopoiesis and JAK2V617F-positive ET associated with cerebral ...
Considering JAK2 V617F -positive disease, a higher (>50%) JAK2 V617F burden and histological classification are independent prognostic risk factors for disease progression. These findings reinforce the need for standardized detection of this mutation. Copyright 2017 John Wiley & Sons, Ltd....
This might be a clinical implication of the study that says for patients with lower ERBB2 IHC positivity, FOLFOX is a better choice than ipilimumab (offers higher survival). It would have also been nice if the study outcomes would have been stratified according to the gene mutation panels. ...
Shimanovsky A, Bauer F, Silver J et al. A case of polycythemia rubra vera transforming into a chronic phase JAK2 V617F mutation-negative Ph+ chronic myelogenous leukemia. Leuk Lymphoma 2012 [ePub ahead of print].Shimanovsky A, Bauer F, Silver J, Lamana S, Dasanu CA. A case of ...
Both patients were positive for the JAK2 V617F mutation. In the first patient the chronic lymphocytic leukaemia was asymptomatic, stage A, and did not require any additional treatment, while the second patient presented with generalized large lymphadenopathy (stage B) and chronic lymphocytic leukaemia...
JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study. JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F- positive-myeloproliferative neoplasia: a European Leukemia Net ...
In MPNs, this mutation is associated with the germline GGCC (46/1) haplotype. Several studies associated JAK2 haplotype GGCC_46/1 with some MPNs clinical parameters, but not one explore the link between JAK2 haplotype GGCC_46/1 and onco-drug resistance. Thus, we assessed for...
Recently, JAK2V617F mutation introduced as a diagnostic marker for other Myeloproliferative neoplasms. Many studies show that the absence of the JAK2 mutation in chronic phase Philadelphia positive CML. In contrast with these reports, more recently, several cases with the coexistence of Philadelphia ...
Screening for MG in patients with PV positive for JAK2V617F mutation can help in early diagnosis and treatment, resulting in a significant reduction in morbidity and mortality.doi:10.1002/ccr3.3574Sreethish SasiDepartment of Internal Medicine Hamad General Hospital Hamad Medical Corporation Doha Qatar...
4090 Transformation to acute myeloid leukemia (AML) is a known complication of MPN but the role of JAK2V617F mutation is still undefined. In 2006, Campbell described a possible model for the development of a JAK2WT-AML in a patient with JAK2V617F-MPN and more recently, Theocharides et ...